“Growing Adoption of Portable and Home-Based PFT Devices”
- A significant and accelerating trend in the global pulmonary function testing market is the growing adoption of portable and home-based PFT devices, driven by rising demand for decentralized and patient-centric respiratory care. This shift enables broader access to testing, especially in remote or underserved regions, and aligns with the global emphasis on telehealth and chronic disease management
- For instance, companies are developing compact spirometers and handheld PFT devices that connect to smartphones or tablets, allowing patients to perform accurate lung function tests from home. Devices such as the MIR Spirobank Smart and NuvoAir Home Spirometer have shown high usability and comparable accuracy to lab-based equipment, making them viable for routine monitoring of conditions such as COPD and asthma
- These innovations are particularly valuable for managing chronic respiratory conditions, as they enable continuous tracking of lung function without the need for frequent hospital visits. Clinicians can remotely access patient data via cloud-based platforms, identify early signs of deterioration, and adjust treatment plans in real-time—improving patient adherence and outcomes
- The integration of Bluetooth and cloud connectivity in portable PFT systems also enhances data sharing, interoperability with electronic health records (EHRs), and supports AI-based analytics for more informed decision-making. This contributes to a more dynamic, data-driven approach to respiratory care across both primary and specialty settings
- ·As healthcare systems increasingly move towards value-based and preventive care models, the demand for user-friendly, portable pulmonary testing solutions is accelerating. Manufacturers are responding by launching mobile-first devices and software ecosystems that support remote diagnostics and personalized respiratory care pathways
Frequently Asked Questions
One prominent trend in the global pulmonary function testing market is growing adoption of portable and home-based PFT devices.
The growing need due to rising prevalence of respiratory diseases and technological advancements is a major driver contributing.
The concerns regarding high initial costs and lack of skilled professionals, poses a significant barrier to widespread adoption particularly in cost-sensitive markets.
The obstructive lung disease application segment dominated the pulmonary function testing systems market in 2024 with a market share of 39.8%, driven by the high global prevalence of chronic obstructive pulmonary disease (COPD) and asthma and the necessity for continuous monitoring and management of these chronic conditions.
Asia-Pacific is expected to be the fastest-growing region in the pulmonary function testing market during the forecast period, with a projected CAGR of 7.7%, due to increasing urbanization, rising disposable incomes, and improving healthcare infrastructure
